The melanocortin pathway
Sexual arousal in humans has two distinct components: central (CNS-mediated psychological arousal) and peripheral (vascular response). PDE5 inhibitors (sildenafil, tadalafil) work on the peripheral vascular pathway. They support the mechanics but cannot create the central arousal that initiates the process. For people whose dysfunction is central — low desire, reduced sexual responsiveness, hypoactive sexual desire disorder — PDE5 inhibitors are insufficient because they're acting on the wrong layer.
The melanocortin pathway is the central arousal layer. Alpha-MSH (melanocyte-stimulating hormone) and its synthetic analogs bind to the MC4R receptor in the hypothalamus, triggering downstream dopaminergic activation and the integrated central response we experience as desire. PT-141 and Melanotan II are both synthetic melanocortin agonists; they differ in receptor selectivity and side-effect profile.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a cyclic heptapeptide derived from alpha-MSH with selective activity at MC4R. It was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women, with subsequent off-label use in men. The clinical evidence in women is solid: multiple Phase 3 trials show modest but statistically significant improvements in desire scores (Kingsberg et al., Obstet Gynecol, 2019, PMID: 30640225).
The effect is typically experienced 30–60 minutes after subcutaneous injection and lasts 4–6 hours. Standard dose: 1.75 mg SC, used as needed pre-event, no more than 8 times per month. Side effects include nausea (about 40% incidence at standard dose), flushing, and occasional headache. The nausea is the dominant tolerability concern; starting at a lower dose (0.5 mg) and titrating up reduces incidence.
Melanotan II
Melanotan II is the older, less-selective melanocortin agonist. It was originally developed for skin tanning (it activates MC1R, increasing melanin production) but its libido-enhancing effects were prominent in early clinical trials and gave rise to its current research use. Melanotan II is non-selective across MC1R, MC3R, MC4R, and MC5R; the broader receptor profile means stronger libido effects than PT-141 in some users, but also broader side effects (skin darkening, mole development, nausea, occasionally fatigue).
Typical research dose: 250–500 mcg SC, titrated from very low starting doses (50 mcg) to assess tolerability. Used as needed pre-event, with extended washouts between sessions. Long-term effects on skin and mole development are real considerations — anyone with a personal or family history of melanoma should not use Melanotan II.
Supporting peptides
For libido complaints with a hormone-axis component, the GH-pair (CJC-1295/Ipamorelin) and/or Sermorelin can support the underlying endocrine environment without directly acting on libido. For libido issues secondary to chronic stress, Selank may address the anxiety-driven component.
Protocols
Beginner (PT-141 trial): Start at 0.5 mg SC, 60 minutes before intended use. If well tolerated, titrate to 1.0 mg next session. Most users find the right dose between 1.0 and 1.75 mg. Use no more than 8 times per month.
Intermediate (Melanotan II trial): Start at 50 mcg SC for first session to assess tolerability (nausea is the main concern). Increase by 50 mcg per session up to 250–500 mcg as needed. Skin sensitivity and mole monitoring required.
Safety
Both peptides have well-characterized side effects. PT-141: nausea (most common), flushing, headache, transient blood pressure elevation (avoid in uncontrolled hypertension). Melanotan II: nausea, skin darkening, mole development, occasional priapism in men. Either should be avoided in people with personal or family history of melanoma, uncontrolled cardiovascular disease, or melanocortin-receptor-related disorders.
References
- Kingsberg SA, Clayton AH, et al. Bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019. PMID: 30640225.
- Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007.
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide. J Sex Med. 2006.
Versus PDE5 inhibitors
PT-141 and Melanotan II act on central arousal mechanisms; sildenafil and tadalafil act on peripheral vascular response. They are not substitutes for each other and they target different patient profiles. For someone whose dysfunction is primarily mechanical-vascular (erectile dysfunction without low desire), PDE5 inhibitors are first-line. For someone whose dysfunction is primarily central (low desire, hypoactive sexual desire disorder), the melanocortin peptides are mechanistically appropriate. Some patients benefit from layered approaches, but this should be done under clinical guidance — the cardiovascular load can compound.
Hormone axis evaluation
Before starting any libido-focused peptide, baseline hormone evaluation is appropriate: total and free testosterone, SHBG, prolactin, TSH, DHEA-S, estradiol (men and women). Low libido secondary to hypogonadism, hyperprolactinemia, or thyroid dysfunction should be addressed at the source; peptide approaches are less likely to succeed in those contexts.
Psychological factors
Libido is multifactorial. Stress, relationship dynamics, sleep, and mood have at least as much effect on desire as any pharmacological intervention. The peptide approaches are useful when the upstream factors are addressed and the central arousal system remains the bottleneck. They are less useful — and may be counterproductive — when used to override an unfavorable psychological or relational context.